Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Final Coverage-With-Evidence-Development Guidance Delayed By CMS Staff Cuts

This article was originally published in The Gray Sheet

Executive Summary

The CMS coverage and analysis group has had to divert its attention from finishing a CED guidance to finalizing proposed changes to the process for awarding Medicare coverage for IDE trials, primarily due to staff cuts, says Louis Jacques, who heads the group.

You may also be interested in...



Louis Jacques On Coverage, Evidence And IDEs

Former CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.

Louis Jacques On Coverage, Evidence And IDEs

In the first part of a two-part Q&A, just-departed CMS coverage director Louis Jacques talks about the strong future ahead he envisions for the Medicare coverage-with-evidence-development program and new coverage policies that will be implemented for investigational device exemption trials.

People Briefs: Louis Jacques To Leave CMS; FDA, MHRA Appointments

Louis Jacques, who directs CMS’ coverage office, will leave the agency at the end of the month. FDA appoints acting deputy chief scientist. The U.K. Medicines and Healthcare products Regulatory Agency names clinical director of medical devices. More people briefs.

Related Content

Topics

UsernamePublicRestriction

Register

MT032574

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel